Mineralys Therapeutics: Positive Q3 Results, Nearing FDA Submission
Update: 2025-11-11
Description
Mineralys Therapeutics, a high blood pressure medicine developer, reported a smaller loss than expected in Q3, but stocks still fell due to investor concerns about drug approval. The companys loss per share decreased from 96 cents to 52 cents, aided by reduced R&D costs. Mineralys raised $287.5 million in September, ending Q3 with a $593.6 million cash reserve. CEO Jon Congleton expressed excitement, as the company prepares to submit its New Drug Application for lorundrostat, with initial results for obstructive sleep apnea trial expected in Q1 2026.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
